Aprea Therapeutics (NASDAQ:APRE) Lowered to Strong Sell Rating by Zacks Research

Zacks Research downgraded shares of Aprea Therapeutics (NASDAQ:APRE) from a hold rating to a strong sell rating in a research report report published on Tuesday,Zacks.com reports.

Other equities analysts have also issued research reports about the stock. HC Wainwright reduced their price objective on shares of Aprea Therapeutics from $20.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday, December 18th. Weiss Ratings reissued a “sell (e+)” rating on shares of Aprea Therapeutics in a research note on Wednesday, October 8th. Two analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $8.00.

Aprea Therapeutics Stock Performance

NASDAQ APRE remained flat at $0.90 on Tuesday. The company’s stock had a trading volume of 5,820 shares, compared to its average volume of 84,272. The stock’s 50 day moving average price is $1.03 and its two-hundred day moving average price is $1.40. The company has a market capitalization of $6.29 million, a P/E ratio of -0.42 and a beta of 1.44. Aprea Therapeutics has a 52-week low of $0.84 and a 52-week high of $4.65.

Aprea Therapeutics (NASDAQ:APRE) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.36). Aprea Therapeutics had a negative return on equity of 88.12% and a negative net margin of 2,666.46%.The firm had revenue of $0.00 million during the quarter. Research analysts predict that Aprea Therapeutics will post -2.55 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Marc Duey bought 21,459 shares of the firm’s stock in a transaction on Wednesday, December 10th. The stock was bought at an average price of $1.17 per share, with a total value of $25,107.03. Following the purchase, the director directly owned 256,155 shares of the company’s stock, valued at approximately $299,701.35. This represents a 9.14% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 13.63% of the company’s stock.

About Aprea Therapeutics

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.